According to a newly published market research report by 24LifeSciences, global bispecific T cell engager therapeutics market was valued at USD 5.8 billion in 2024 and is projected to reach USD 20.1 billion by 2032, growing at a compound annual growth rate (CAGR) of 15.8% during the forecast period 20252032. Bispecific T cell engagers (BiTEs) represent a revolutionary class of...

The biopharmaceutical excipients market is on the brink of substantial expansion, projected to reach a remarkable USD 12.4 billion by 2035. This growth reflects an impressive compound annual growth rate (CAGR) of 5.09% from its anticipated 2024 value of USD 7.18 billion. As the demand for advanced drug formulations accelerates, particularly in North America, this sector is becoming increasingly...

The anti-PD-1 antibody industry is experiencing significant momentum as immunotherapy continues to transform cancer treatment approaches worldwide. Growing investments in oncology research, expanding clinical applications, and increasing awareness of immune checkpoint inhibitors are creating new opportunities across healthcare systems. The Global Anti-PD-1 Antibody Market Future Trends reflect...

According to a newly published market research report by 24LifeSciences, global bispecific T cell engager therapeutics market was valued at USD 5.8 billion in 2024 and is projected to reach USD 20.1 billion by 2032, growing at a compound annual growth rate (CAGR) of 15.8% during the forecast period 20252032. Bispecific T cell engagers (BiTEs) represent a revolutionary class of...

According to a newly published market research report by 24LifeSciences, global human microbiome therapeutics market was valued at USD 1,016 million in 2024 and is projected to reach USD 1,705 million by 2031, growing at a compound annual growth rate (CAGR) of 7.9% during the forecast period 2024–2031. The human microbiome represents one of the most promising frontiers in modern medicine,...

According to a new report from Intel Market Research, the global Pembrolizumab market was valued at USD 21.8 billion in 2025 and is projected to grow from USD 24.3 billion in 2026 to USD 42.7 billion by 2034, exhibiting a robust CAGR of 7.3% during the forecast period. This growth is driven by increasing cancer prevalence, rising immunotherapy adoption, expanding regulatory approvals for new...